Cancer Predisposition_Paediatric

Gene: FBXW7

Amber List (moderate evidence)

FBXW7 (F-box and WD repeat domain containing 7)
EnsemblGeneIds (GRCh38): ENSG00000109670
EnsemblGeneIds (GRCh37): ENSG00000109670
OMIM: 606278, Gene2Phenotype
FBXW7 is in 4 panels

2 reviews

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

I don't know

Somatic FBXW7 variants are common in a range of cancer types (~3.5% of all cancers) including Wilms tumour (PMID 20332316) with COSMIC indicating ~60% of somatic variants are missense substitutions. There is low-moderate evidence that FBXW7 is a tumour suppressor gene (PMID 28572459).

Germline FBXW7 loss of function variants have been linked to developmental disability with/without distinctive facial differences . Stephenson et al discuss the phenotype of 35 individual patients from 32 families and the strong evidence for the gene's role in neuro-development, thus providing evidence for FBXW7 variants being causally linked to a neuro-developmental phenotype with variable expression and penetrance (PMID 35395208). None of the 35 patients in this cohort were reported to have cancer (including no Wilms tumours).

A 2019 exome based study (890 individuals with Wilms tumour), which aimed to discover new Wilms tumour predisposition genes, identified 4 individuals with FBXW7 truncating variants (PMID 30885698). The neurodevelopmental phenotype of the 4 individuals was not reported in detail (one was reported to have hypotonia). No tumour sequence was reported, thus it is not known if there was somatic loss or mutation of the wild type allele.

Roversi et al report a patient with small stature, macrocephaly, focal segmental glomerulosclerosis requiring immunosuppression (from 17 years) followed by renal transplant (27 years), and multiple tumours (Hodgkin’s lymphoma at 18 years, ovarian cystadenoma at 24 years, Wilms at 32 years, breast at 34 years). The patient had an aCGH detected 157kb constitutional deletion involving most of FBXW7. Sanger sequencing and MLPA of TP53, BRCA1, BRCA2, PALB2 and WT1 genes, peripheral blood karyotype and methylation specific MLPA of 11p15 were also reported (no abnormality detected). No chromosome fragility studies or other genomic testing was reported. They did not identify a second hit in FBXW7 in Wilms tumour tissue.
Created: 28 Nov 2022, 12:10 a.m. | Last Modified: 28 Nov 2022, 12:10 a.m.
Panel Version: 0.126

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Phenotypes
Wilms tumour, hereditary, MONDO:0003321, FBXW7-related

Laura Raiti (Royal Children's Hospital, Melbourne)

Green List (high evidence)

PMID: 30885698
4 individuals with germline truncating variants in FBXW7. Highly intolerant to protein-truncating variants with pLI score= 1.
- 1 individual developed a second malignancy (osteosarcoma) as an adult in addition to childhood Wilms tumour.
- 1 individual had a de novo missense variant (a child with an extra-renal rhabdoid tumour)

PMID: 26482194
1 patient with Hodgkin lymphoma, adult Wilms tumour, early-onset breast cancer, and a constitutional FBXW7 deletion was reported
Sources: Literature
Created: 11 Jul 2021, 5:36 a.m.

Mode of inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted

Publications

Details

Mode of Inheritance
MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted
Sources
  • Expert Review Amber
Phenotypes
  • Wilms tumour, hereditary, MONDO:0003321, FBXW7-related
OMIM
606278
Clinvar variants
Variants in FBXW7
Penetrance
None
Publications
Panels with this gene

History Filter Activity

28 Nov 2022, Gel status: 2

Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Phenotypes for gene: FBXW7 were changed from Predisposition to cancer to Wilms tumour, hereditary, MONDO:0003321, FBXW7-related

28 Nov 2022, Gel status: 2

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: fbxw7 has been classified as Amber List (Moderate Evidence).

26 Aug 2021, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: fbxw7 has been classified as Green List (High Evidence).

26 Aug 2021, Gel status: 3

Set Phenotypes

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Phenotypes for gene: FBXW7 were changed from to Predisposition to cancer

26 Aug 2021, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services; Australian Genomics)

Gene: fbxw7 has been classified as Green List (High Evidence).

11 Jul 2021, Gel status: 0

Created, Added New Source, Set mode of inheritance, Set publications

Laura Raiti (Royal Children's Hospital, Melbourne)

gene: FBXW7 was added gene: FBXW7 was added to Cancer Predisposition_Paediatric. Sources: Literature Mode of inheritance for gene: FBXW7 was set to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted Publications for gene: FBXW7 were set to PMID: 30885698; PMID: 26482194 Review for gene: FBXW7 was set to GREEN